期刊文献+

临床试验方法的选择:有效性研究和疗效研究 被引量:1

原文传递
导出
摘要 临床试验(clinicaltrial)的分类方法有很多。根据Roland和Torgerson的观点,可以将临床试验划分为说明性(explanatory)和实用性(pragmatic)两大类。一般来说,说明性试验评估的是疗效(efficacy),即在理想条件下某种治疗所带来的益处,受试者常常被严格定义和筛选;而实用性研究评估的则是有效性(effectiveness),即在日常临床条件下治疗的获益。
作者 司天梅 王刚
出处 《中华精神科杂志》 CAS CSCD 北大核心 2010年第1期1-2,共2页 Chinese Journal of Psychiatry
  • 相关文献

参考文献8

  • 1Roland M,Torgerson D.Understanding controlled trials:what outcomes should be measured? B M J,1998,317:1075-1080.
  • 2Meltzer HY,Bobo WV.Interpreting the efficacy findings in the CATIE study:what clinicians should know.CNS Spectr,2006,11(7 Suppl):14-24.
  • 3Claassen CA,Trivedi MH,Rush A J,et al.Clinical differences among depressed patients with and without a history of suicide attempts:findings from the STAR * D trial.J Affect Disord,2007,97(1/3):77-84.
  • 4Lieberman JA,Stroup TS,McEvoy JP,et al.Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.N Engl J Med,2005,353:1209-1223.
  • 5Weiden PJ,Preskorn SH,Fahnestock PA,et al.Translating the psychopharmacology of antipsychotics to individualized treatment for severe mental illness:a roadmap.J Clin Psychiatry,2007,68(7 Suppl):1-48.
  • 6闫俊,张鸿燕,舒良,李华芳,顾牛范,王刚,蔡焯基,肖卫东,王高华,谢世平,张心保,李婷,马崔,姚晨.阿立哌唑与利培酮治疗精神分裂症的随机双盲多中心对照研究[J].中华精神科杂志,2008,41(2):81-84. 被引量:22
  • 7罗炯,马辛,母生梅,聂长杰,房萌,谭云龙,曹毅,祁富生,何卫宁,陈红辉,王晓萍,薛志敏,张敬悬,高安民,袁国桢,晏云兴,张少平,杨汉清,况利,唐伟,林崇光,钱惠忠,冯斌,王刚.注射用利培酮微球治疗精神分裂症的疗效和安全性研究[J].中华精神科杂志,2010,43(1):14-18. 被引量:14
  • 8李华芳,沈一峰,王刚,李鸣,张晋碚,赵振环,范剑雄,周沫,贾福军,孙学礼,顾牛范.注射用利培酮微球对精神分裂症患者维持治疗的疗效和安全性研究[J].中华精神科杂志,2010,43(1):8-13. 被引量:7

二级参考文献39

  • 1田成华,司天梅,舒良.第一个长效非典型抗精神病药:注射用利培酮微球[J].中国新药与临床杂志,2004,23(10):723-725. 被引量:11
  • 2尚岚,孙士友.长效抗精神病针剂的临床运用[J].国外医学(精神病学分册),1996,23(2):107-110. 被引量:3
  • 3Marcus R, Kostic D, McQuade R. et al. Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder [ J/ OL]. Schizophr Bull, 2005,31 (2) :499 [ 2007-12-19 ]. http:// gateway, tx. ovid. com.
  • 4Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry., 2003, 60:681-690.
  • 5Pigott TA, Carson WH, Saha AR, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry., 2003, 64:1048-1056.
  • 6Chrzanowski WK, Marcus RN, Torbeyns A, et al. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharrnacology ( Berl ), 2006, 159 : 259- 266.
  • 7Cassano GB, Fagiolini A, Lattanzi L, et al. Aripiprazole in the treatment of schizophrenia: a consensus report produced by schizophrenia experts in Italy. Clin Drug Investig, 2007, 27 : 1- 13.
  • 8Tandon R, Marcus RN, Stock EG, et al. A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: broad effectiveness trial with aripiprazole ( BETA ) . Schizophr Res, 2006, 84:77-89.
  • 9Bardin L, Auclair A, Kleven MS, et al. Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/ serotonin 5-HT1A activity conventional antipsychotics. 118. comparison with typical and atypical Behav Pharmacol, 2007, 18: 103-
  • 10Jordan S, Koprivica V, Chen R, et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol, 2002, 441 : 137-140.

共引文献37

同被引文献4

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部